MVT *in* Silico

A life sciences innovation company.

London, Canada.

Presenters.

Dr. SR Kharche.

CEO & CSO.

Ms Harpreet Kaur.

Business Manager.

Mr. Yihang Cheng.

R&D Support Officer.

June 11, 2025.

?

Problem.

All stakeholders want an improved medical tech R&D standards.

1

It's unacceptably expensive to innovators, uncontrolled enterprise pipeline expenditure.

R&D cost for devices > $100M, drugs > $1B.

2

It's excruciatingly time consuming to both innovators & patients.

Years to decades.

3

It still fails in unexpected ways, patients at risk.

> 90% failure at regulatory & market stages.

Solution.

Leveraging our expertise & validation stage core technology to address the problem.

Our expertise:
FEA, biomechanics, fluid dynamics, biochemistry, micro-physiological systems.

Proprietary, repeatable, codifiable core tech:
Virtual & benchtop product testing platform, **mvtisNAMs**.

✓

1. Dev efficiency.

- 60% reduction in materials/animal use.
- Shorter timelines limit personnel costs.
- Other savings.

✓

2. Shorter dev cycles.

50% shorter timelines from design to prototype, weeks to months.

✓

3. Improved success rates.

Platform generated evidence feeds into patent applications.

What does the customer get?

Value proposition.

1

Cost reduction.

- Reduced salary & material costs.
- Higher quality & derisked product.

2

Shorter time to market.

- Streamlined R&D → fast product to market.
- Derisked patent application.

3

Patient benefits.

- Virtual clinical trial → no control arm.

Business model.

Multiple revenue streams, prime opportunity to give back to society.

1 B2B contracts. → MRR, long term fixed fee.

2 Corporate partnerships. → MRR, targeted innovation, asset development.

3 Asset trading. → Licensing, MRR, lone off asset sale.

4 Public service activities. → Reputation building, synthetic data, network effect revenue.

Business development in phase.

Phase I outcomes:
i. A DDS optimization process.
ii. A PGX test for women.

Develop innovation.

Secure IP.

Monetize.

Contract with a Toronto based SME:
Optimization of a subcutaneous (skin) drug delivery system (an injection-drug combination).

How it works.

Phase 1 project #1: Optimizing a DDS system.

Step 1.
MVTiS creates internal NAM models to generate testable predictions: Does the biomechanics, physiology, pharmacology work, is it safe?

Step 2.
Client's R&D become streamlined, shorter dev cycle.

Step 3.
MVTiS performs virtual clinical trial: what is the safety, toxicity, & efficacy in populations with various skin types?

Step 4.
Client's clinical trial has no need for a control arm.

Step 5.
Client uses evidence provided by MVTiS in their regulatory processes with reduced recall risk/legal costs.

How it works.

Phase 1, project #2: Undiagnosed endometriosis patients cannot self medicate for pain relief, sleep disorders.

Product (validation stage):
A pharmacogenomics ADR test.

1. Patient buys test in a pharmacy, family practice.

2. Patient self-administers the hormone (part I), gets **instant warning signal.**

3. Patient provides a saliva swab (part II) for our lab analysis.

4. MVTiS performs ADR assessment, **provides test report within one day.**

Early disease stage referral for full diagnostics, better chance of management.

MVTiS uses the real world data to improve the test’s accuracy/specificity.

Continuous product improvement, new applications.

Phase I (2026-27) revenue streams:
Women's health products.

Targeting high value, high impact markets.

1

DDS development.

Enterprise partnerships.

2

PGx ADR test kit.

Pharmacy & family practice contracts.

Competitive advantages.

MVTiS has many advantages.

We address many hard to solve problems.

	CFD Life (Japan).	Computational Life (Italy).	Intrepid labs, Toronto.	StokedBio, Hamilton.	MVT *in* Silico. Canada.
Synthetic data.	✓	✓	✓	✓	✓
In vitro data.			✓		✓
Toxicity/ Failure opt.			✓	✓	✓
Device opt.	✓	✓			✓
Drug opt.			✓	✓	✓
Knowledge driven AI.	✓	✓	✓	✓	✓
Virtual clinical trials.		✓			✓

Progress.

Milestones: Past & future.

Adopting a lean approach, there is steady progress with profit expected in Q2 2026.

2023	2024	2025	2026.
Incorporation.	Version 1 of MVP. Secured two beta clients, started work on 1 patent.	MVP (version 2), 2 employees, initiated fundraising, initiated 1 product and 1 process patent projects.	To establish wet lab, full operations, marketing & sales.
$10k.	$20k.	$150k (founder investment). Non-dilutive $10k.	Profitable venture by end of 2026, growth after that.

Team.

An expert team poised for success, additional skill sets upcoming.

Dr. Sanjay Kharche.
Founder, CEO, CSO.

Prof. D. G. Welsh.
Advisor. Pharmacology expert.

Harpreet Kaur.
Business strategy manager.

Yihang Cheng.
R&D officer.

CFO.
Under negotiation.

IP expert.
Under negotiation.

Marketing & sales.
Under negotiation.

Ask and purpose.

An investment opportunity: We are raising $1.5M, and leverage it to $3M.

With a runway to Q4 2027 (scheduled next raise), your $s ensure expansion, a large ROI, and puts us together on a growth & profit trajectory!



Key takeaways.

Contact.
Dr. SR Kharche.
sumus@mvtinsilico.ca
5198780685

https://www.mvtinsilico.ca
London Canada.

- ❑ A better approach to R&D.
- ❑ World class team.
- ❑ Evident scalability.
- ❑ Raising pre-seed CAD$1.5M, seed strapping ahead.
- ❑ Provisional patent application in preparation for Q4 2025.
- ❑ Investor negotiations in progress.
- ❑ Market launch of by Q3 2026, likely sooner.